Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1: PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F16%3A00066737" target="_blank" >RIV/65269705:_____/16:00066737 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00092818

Výsledek na webu

<a href="http://www.oraloncology.com/article/S1368-8375(16)30135-X/abstract" target="_blank" >http://www.oraloncology.com/article/S1368-8375(16)30135-X/abstract</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.oraloncology.2016.08.007" target="_blank" >10.1016/j.oraloncology.2016.08.007</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1: PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al

Popis výsledku v původním jazyce

As addressed by Pai with co-workers in their comprehensive review, novel immunotherapeutic strategies using immune checkpoint inhibitors represent a promising area of research in squamous cell carcinoma of the head and neck (SCCHN) [1]. Results from a phase III trial and preliminary data from three early clinical studies demonstrated the efficacy of monoclonal antibodies against programmed death-1 (PD-1) receptor (nivolumab, pembrolizumab) and its ligand PD-L1 (durvalumab) as second-line treatments in the recurrent and/or metastatic (R/M) setting. With relatively low incidence of serious adverse events, these agents elicited durable responses even in patients with refractory disease. Moreover, nivolumab, as the first drug ever, significantly improved overall survival (OS) by 2.4 months compared with investigator's choice (single-agent chemotherapy or cetuximab) [1-4]. From a broader perspective, these pioneering studies have important implications for future trial design with one of the challenges being the selection of appropriate clinical endpoints associated with benefits of immune checkpoint inhibitors.

Název v anglickém jazyce

Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1: PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al

Popis výsledku anglicky

As addressed by Pai with co-workers in their comprehensive review, novel immunotherapeutic strategies using immune checkpoint inhibitors represent a promising area of research in squamous cell carcinoma of the head and neck (SCCHN) [1]. Results from a phase III trial and preliminary data from three early clinical studies demonstrated the efficacy of monoclonal antibodies against programmed death-1 (PD-1) receptor (nivolumab, pembrolizumab) and its ligand PD-L1 (durvalumab) as second-line treatments in the recurrent and/or metastatic (R/M) setting. With relatively low incidence of serious adverse events, these agents elicited durable responses even in patients with refractory disease. Moreover, nivolumab, as the first drug ever, significantly improved overall survival (OS) by 2.4 months compared with investigator's choice (single-agent chemotherapy or cetuximab) [1-4]. From a broader perspective, these pioneering studies have important implications for future trial design with one of the challenges being the selection of appropriate clinical endpoints associated with benefits of immune checkpoint inhibitors.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Oral oncology

ISSN

1368-8375

e-ISSN

—

Svazek periodika

62

Číslo periodika v rámci svazku

NOV

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

2

Strana od-do

"E3"-"E4"

Kód UT WoS článku

000392635300002

EID výsledku v databázi Scopus

—